Read more
12:17 PM ยท 20 February 2026

US500: US stocks lose momentum despite the strongest S&P 500 revenue growth in 3 years ๐Ÿ“Š

-
-
Open account Download free app

US500 is trying to stabilize after recent declines, making it a good moment to take stock of the Q4 2025 earnings season. US corporates are accelerating again, not only in profits but also in top-line growth. From a fundamentals perspective, revenue momentum is at least as important as earnings, because it speaks directly to underlying demand rather than cost or margin effects. The S&P 500’s blended revenue growth rate for Q4 currently stands at 9% y/y, the strongest in three years. If this holds through the end of reporting season, it would mark the index’s highest revenue growth since Q3 2022 (11.0%). Importantly, revenue growth expectations have been revised higher throughout the season.

  • 9% y/y: current S&P 500 blended revenue growth for Q4

  • 7.8%: estimate as of December 31, 2025

  • 6.5%: estimate as of September 30, 2025

  • 10 out of 11 sectors are reporting y/y revenue growth

  • Three sectors are posting double-digit revenue growth: Information Technology, Communication Services, Health Care

The biggest contribution comes from four sectors.

Information Technology: Revenue growth increased to 20.6% from 17.9%

Key positive surprises:

  • Apple: $143.76bn vs $138.39bn expected

  • Super Micro Computer: $12.68bn vs $10.42bn expected

  • Microsoft: $81.27bn vs $80.31bn expected

Health Care: Revenue growth increased to 10.3% from 9.0%

Positive surprises:

  • Cigna: $72.50bn vs $70.31bn expected

  • CVS Health: $105.69bn vs $103.70bn expected

  • Eli Lilly: $19.29bn vs $17.94bn expected

  • Centene: $49.73bn vs $48.39bn expected

Communication Services: Revenue growth increased to 12.2% from 10.2%

Key reports:

  • Alphabet: $113.83bn vs $111.32bn expected

  • Meta: $59.89bn vs $58.46bn expected

Industrials: Revenue growth increased to 7.8% from 5.8%

Positive surprises:

  • Boeing: $23.95bn vs $22.60bn expected

  • RTX: $24.24bn vs $22.69bn expected

  • Caterpillar: $19.13bn vs $17.85bn expected

Other notable upside surprises

  • Apollo Global Management: $9.86bn vs $4.77bn expected

  • Phillips 66: $36.33bn vs $33.86bn expected

  • Amazon: $213.39bn vs $211.44bn expected

  • Ford: $45.90bn vs $43.60bn expected

What’s next: forecasts are already cooler

Analysts expect revenue growth to slow through 2026:

  • Q1 2026: 8.7% y/y

  • Q2 2026: 7.9%

  • Q3 2026: 7.3%

  • Q4 2026: 7.4%

US500 (D1 timeframe)

FactSet’s earnings-season data look strong, yet this has not translated into an acceleration in S&P 500 futures. That divergence is somewhat concerning, as it may suggest valuations moved ahead of earnings and stocks are priced to perfection, leaving less room for upside. On the other hand, both earnings and revenue momentum still provide tangible support for the US market’s relatively elevated valuation levels.

Source: xStation5

3 April 2026, 6:58 PM

Three Markets to Watch in the Week Ahead (03.04.2026)

3 April 2026, 6:31 PM

Daily Summary: A Lull in the Pre-Holiday Calm

3 April 2026, 4:50 PM

Market wrap ๐Ÿ“ŒUS indices in focus amid strong NFP data and $100 oil

3 April 2026, 4:32 PM

BREAKING: NFP payrolls skyrocket ๐Ÿš€ EURUSD back in red ๐Ÿ“‰

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.